Section Arrow
HIND.NASDAQ
- Vyome Holdings Inc
Quotes are at least 15-min delayed:2026/04/20 16:09 EDT
After Hours
Last
 2.34
-- (--)
Bid
2.2
Ask
2.37
High 2.34 
Low 2.34 
Volume
Regular Hours (Closed)
Last
 2.35
+0.14 (+6.33%)
Day High 
2.38 
Prev. Close
2.21 
1-M High
2.43 
Volume 
24.25K 
Bid
2.2
Ask
2.37
Day Low
2.17 
Open
2.22 
1-M Low
2.02 
Market Cap 
15.51M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 2.22 
20-SMA 2.21 
50-SMA 2.51 
52-W High 56.38 
52-W Low 1.75 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.86/-1.03
Enterprise Value
15.51M
Balance Sheet
Book Value Per Share
0.35
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
319.71K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TOVXTheriva Biologics Inc0.46+0.2028+78.85%0.09PE
After Hours 0.4171 -0.0429 -9.33%
CMNDClearmind Medicine Inc.1.14+0.4204+58.42%-- 
After Hours 1.26 +0.12 +10.53%
ENVBEnveric Biosciences Inc.3.62+1.8+98.90%0PE
After Hours 3.58 -0.04 -1.10%
ATAIAtaiBeckley Inc4.9+0.87+21.59%-- 
After Hours 4.87 -0.03 -0.61%
PBMPsyence Biomedical Ltd.11.3+3.7+48.68%-- 
After Hours 11.2 -0.1 -0.88%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.